1
|
Dobbin-Williams K, Crossman R, Swab M. Experiences of parents of teenagers with life-threatening food allergies: a qualitative systematic review protocol. JBI Evid Synth 2024; 22:2170-2176. [PMID: 39039829 DOI: 10.11124/jbies-23-00380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/24/2024]
Abstract
OBJECTIVE The objective of this review is to synthesize the experiences of parents of teenagers with life-threatening food allergies. INTRODUCTION Life-threatening food allergies are increasing globally, with a significant effect on families, particularly parents. The teenage years are a time of increasing autonomy for young people; however, for parents living with and caring for a teenager with a life-threatening food allergy, this responsibility can have a considerable impact. INCLUSION CRITERIA This review will include qualitative studies on the experiences of parents of teenagers with life-threatening food allergies, including, but not limited to, caregiving, parenting, and psychosocial experiences; any day-to-day activities, happenings, thoughts, or feelings related to parenting a teenager with life-threatening food allergies; and the handing over of responsibility for the allergy to the teenager. The review will include studies on participants in the community and in health care settings such as inpatient hospitalizations, outpatient visits, school and sports events, family dinners, restaurants, and travel. Participants from all cultural backgrounds, socio-economic backgrounds, and countries will be included. METHODS The review will follow the JBI methodology for systematic reviews of qualitative evidence. The search for published studies will include CINAHL, MEDLINE, and PsycINFO (EBSCOhost); Embase (Ovid); LILACS, IBSS, and Sociological Abstracts (ProQuest). The search for unpublished studies will include ProQuest Dissertations and Theses, Open Access Theses and Dissertations (OATD), Bielefeld Academic Search Engine (BASE), Google, and Google Scholar. Databases will be searched from inception until the present. JBI tools and guidelines will be used to conduct critical appraisal, data extraction, data synthesis, and assessment of confidence in the findings. REVIEW REGISTRATION PROSPERO CRD42024503698.
Collapse
Affiliation(s)
- Karen Dobbin-Williams
- Faculty of Nursing, Memorial University of Newfoundland, St. John's, NL, Canada
- Memorial University Nursing Collaboration for Evidence-based Health Care: A JBI Affiliated Group, Memorial University of Newfoundland, St. John's, NL, Canada
| | - Renee Crossman
- Faculty of Nursing, Memorial University of Newfoundland, St. John's, NL, Canada
- Memorial University Nursing Collaboration for Evidence-based Health Care: A JBI Affiliated Group, Memorial University of Newfoundland, St. John's, NL, Canada
| | - Michelle Swab
- Memorial University Nursing Collaboration for Evidence-based Health Care: A JBI Affiliated Group, Memorial University of Newfoundland, St. John's, NL, Canada
- Health Sciences Library, Memorial University of Newfoundland, St. John's, NL, Canada
| |
Collapse
|
2
|
Messina NL, Gardiner K, Pittet LF, Forbes EK, Francis KL, Freyne B, Zufferey C, Abruzzo V, Morison C, Turner H, Allen KJ, Flanagan KL, Ponsonby AL, Robins-Browne R, Shann F, Vuillermin P, Donath S, Casalaz D, Curtis N. Neonatal BCG Vaccination for Prevention of Allergy in Infants: The MIS BAIR Randomised Controlled Trial. Clin Exp Allergy 2024; 54:682-693. [PMID: 39004434 DOI: 10.1111/cea.14537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Revised: 06/27/2024] [Accepted: 06/29/2024] [Indexed: 07/16/2024]
Abstract
BACKGROUND The beneficial off-target effects of Bacille Calmette-Guérin (BCG) vaccination potentially include protection against allergy. OBJECTIVE In the MIS BAIR trial, we aimed to determine whether neonatal BCG vaccination reduces atopic sensitisation and clinical food allergy in infants. METHODS In this randomised controlled trial, 1272 neonates were allocated to BCG-Denmark vaccine (0.05 mL intradermal dose) or no BCG at birth. Randomisation was stratified by recruitment site, mode of delivery and plurality of birth. The primary outcome was the incidence of atopic sensitisation determined by skin prick test at 1 year of age. Food allergy was determined by 3-monthly online questionnaires and oral food challenges. Data were analysed by intention-to-treat using binary regression. CLINICALTRIALS gov (NCT01906853). RESULTS Atopic sensitisation during the first year of life was 22.9% among infants in the BCG group and 18.9% in the control group (adjusted risk difference (aRD) 3.8% (95% CI -1.5 to 9.1) after multiple imputation). Clinical food allergy was similar between infants in the BCG and control groups (9.8% vs. 9.6%; aRD 0.2, 95% CI -3.4 to 3.8). An interaction was observed between the primary outcome and maternal history of BCG vaccination. No interaction was observed for the additional prespecified potential effect modifiers tested (sex, delivery mode, family history of any allergy, season of birth, hepatitis B vaccination at randomisation, BCG scar and age at BCG administration). CONCLUSIONS AND CLINICAL RELEVANCE Neonatal BCG-Denmark vaccination does not protect against atopic sensitisation or clinical food allergy in the first year of life.
Collapse
Affiliation(s)
- Nicole L Messina
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Kaya Gardiner
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of General Medicine, Department of Research Operations, Infectious Diseases Unit, The Royal Children's Hospital, Parkville, Victoria, Australia
| | - Laure F Pittet
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
- Paediatric Immunology, Vaccinology, Rheumatology and Infectious Diseases Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Emily K Forbes
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
| | - Kate L Francis
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Bridget Freyne
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
- School of Medicine, University College, Dublin, Ireland
- Department of Paediatric Infectious Diseases, Children's Health Ireland, Dublin, Ireland
| | - Christel Zufferey
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
| | - Veronica Abruzzo
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
| | - Clare Morison
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
| | - Hannah Turner
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
| | - Katrina J Allen
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
| | - Katie L Flanagan
- School of Medicine, University of Tasmania, Hobart, Tasmania, Australia
- Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, Tasmania, Australia
- School of Health and Biomedical Science, RMIT University, Melbourne, Victoria, Australia
| | - Anne-Louise Ponsonby
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Roy Robins-Browne
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Frank Shann
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Peter Vuillermin
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Institute of Mental and Physical Health and Clinical Translation, Deakin University, Geelong, Victoria, Australia
- Child Health Research Unit, Barwon Health, Geelong, Victoria, Australia
| | - Susan Donath
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Dan Casalaz
- Neonatal Intensive Care Unit, Mercy Hospital for Women, Heidelberg, Victoria, Australia
| | - Nigel Curtis
- Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Department of Paediatrics, Department of Microbiology & Immunology, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
- Department of General Medicine, Department of Research Operations, Infectious Diseases Unit, The Royal Children's Hospital, Parkville, Victoria, Australia
| |
Collapse
|
3
|
Jimenez-Garcia R, Lopez-de-Andres A, Hernandez-Barrera V, Zamorano-Leon JJ, Cuadrado-Corrales N, de Miguel-Diez J, Del-Barrio JL, Jimenez-Sierra A, Carabantes-Alarcon D. Hospitalizations for Food-Induced Anaphylaxis Between 2016 and 2021: Population-Based Epidemiologic Study. JMIR Public Health Surveill 2024; 10:e57340. [PMID: 38940759 PMCID: PMC11387914 DOI: 10.2196/57340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 03/21/2024] [Accepted: 05/21/2024] [Indexed: 06/29/2024] Open
Abstract
BACKGROUND Food-induced anaphylaxis (FIA) is a major public health problem resulting in serious clinical complications, emergency department visits, hospitalization, and death. OBJECTIVE This study aims to assess the epidemiology and the trends in hospitalizations because of FIA in Spain between 2016 and 2021. METHODS An observational descriptive study was conducted using data from the Spanish National Hospital discharge database. Information was coded based on the International Classification of Diseases, Tenth Revision. The study population was analyzed by gender and age group and according to food triggers, clinical characteristics, admission to the intensive care unit, severity, and in-hospital mortality. The annual incidence of hospitalizations because of FIA per 100,000 person-years was estimated and analyzed using Poisson regression models. Multivariable logistic regression models were constructed to identify which variables were associated with severe FIA. RESULTS A total of 2161 hospital admissions for FIA were recorded in Spain from 2016 to 2021. The overall incidence rate was 0.77 cases per 100,000 person-years. The highest incidence was found in those aged <15 years (3.68), with lower figures among those aged 15 to 59 years (0.25) and ≥60 years (0.29). Poisson regression showed a significant increase in incidence from 2016 to 2021 only among children (3.78 per 100,000 person-years vs 5.02 per 100,000 person-years; P=.04). The most frequent food triggers were "milk and dairy products" (419/2161, 19.39% of cases) and "peanuts or tree nuts and seeds" (409/2161, 18.93%). Of the 2161 patients, 256 (11.85%) were hospitalized because FIA required admission to the intensive care unit, and 11 (0.51%) patients died in the hospital. Among children, the most severe cases of FIA appeared in patients aged 0 to 4 years (40/99, 40%). Among adults, 69.4% (111/160) of cases occurred in those aged 15 to 59 years. Multivariable logistic regression showed the variables associated with severe FIA to be age 15 to 59 years (odds ratio 5.1, 95% CI 3.11-8.36), age ≥60 years (odds ratio 3.87, 95% CI 1.99-7.53), and asthma (odds ratio 1.71,95% CI 1.12-2.58). CONCLUSIONS In Spain, the incidence of hospitalization because of FIA increased slightly, although the only significant increase (P=.04) was among children. Even if in-hospital mortality remains low and stable, the proportion of severe cases is high and has not improved from 2016 to 2021, with older age and asthma being risk factors for severity. Surveillance must be improved, and preventive strategies must be implemented to reduce the burden of FIA.
Collapse
Affiliation(s)
- Rodrigo Jimenez-Garcia
- Department of Public Health & Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | - Ana Lopez-de-Andres
- Department of Public Health & Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | - Valentin Hernandez-Barrera
- Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Universidad Rey Juan Carlos, Alcorcon, Spain
| | - Jose J Zamorano-Leon
- Department of Public Health & Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | - Natividad Cuadrado-Corrales
- Department of Public Health & Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| | - Javier de Miguel-Diez
- Respiratory Care Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Jose L Del-Barrio
- Preventive Medicine and Public Health Teaching and Research Unit, Health Sciences Faculty, Universidad Rey Juan Carlos, Alcorcon, Spain
| | | | - David Carabantes-Alarcon
- Department of Public Health & Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
4
|
Lam HCY, Neukirch C, Janson C, Garcia-Aymerich J, Clausen M, Idrose NS, Demoly P, Bertelsen RJ, Ruiz LC, Raherison C, Jarvis DL. Food hypersensitivity: an examination of factors influencing symptoms and temporal changes in the prevalence of sensitization in an adult sample. Eur J Clin Nutr 2023:10.1038/s41430-023-01284-w. [PMID: 36964270 PMCID: PMC10393775 DOI: 10.1038/s41430-023-01284-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 03/06/2023] [Accepted: 03/10/2023] [Indexed: 03/26/2023]
Abstract
BACKGROUND/OBJECTIVES Food hypersensitivity (FHS) is common, but little is known about the factors associated with severe reactions, age of onset and whether sensitization persists. This study examines the factors associated with self-reported severe food reactions, onset age and the changes in prevalence of sensitization to foods over time in an adult sample. SUBJECTS/METHODS We used data from adults taking part in the European Community Respiratory Health Survey (ECRHS) III (2010-2014) who provided information on food hypersensitivity, including symptoms, suspected culprit food and onset age (n = 4865). A subsample from six countries had serum food-specific IgE tested for 25 core foods and also in 10 years earlier (ECRHS II). We applied logistic regression and McNemar's test for analyses. RESULTS The prevalence of self-reported FHS was 13.5% at ECRHS III. Of those providing information on symptoms (n = 611), 26.4% reported severe reactions. About 80% of 1033 reported food-specific reactions (reported by 596 participants) began after age 15. History of asthma (odds ratio OR 2.12 95% confidence interval CI 1.13-3.44) and a younger age of onset of FHS (OR 1.02, 95% CI 1.01-1.03, per year) were associated with higher risks of a lifetime experience of severe food reactions. In the subsample with IgE tested in both surveys (n = 1612), the overall prevalence of sensitization to foods did not change over 10 years. CONCLUSION Our findings support previous observations of more severe food reactions in people with asthma and that most FHS reported by this sample started after age 15. We found no evidence of changes in the prevalence of sensitization to food in adults followed for 10 years.
Collapse
Affiliation(s)
- Holly C Y Lam
- National Heart and Lung Institute, Imperial College London, London, UK.
- MRC Centre for Environment and Health, Imperial College London, London, UK.
| | - Catherine Neukirch
- Service de Pneumologie, AP-HP, Hôpital Bichat, Université de Paris, INSERM 1152, F-75018, Paris, France
| | - Christer Janson
- Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden
| | - Judith Garcia-Aymerich
- Barcelona Institute of Global Health (ISGlobal), Doctor Aiguader, 88, 08003, Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - Michael Clausen
- Children's Hospital and Department of Allergy, Landspitali University Hospital, 101, Reykjavik, Iceland
| | - N Sabrina Idrose
- Allergy and Lung Health Unit, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, VIC, Australia
- Centre for Food and Allergy Research, Murdoch Children's Research Institute, Parkville, VIC, 3052, Australia
| | - Pascal Demoly
- Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France
| | - Randi J Bertelsen
- Department of Clinical Science, University of Bergen, Bergen, Norway
- Department of Occupational Medicine, Haukeland University Hospital, Bergen, Norway
| | - Lidia C Ruiz
- Social Epidemiology and Health Policy (SEHPO), Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium
| | - Chantal Raherison
- University of Bordeaux, INSERM, BPH, U1219, F-33000, Bordeaux, France
| | - Deborah L Jarvis
- National Heart and Lung Institute, Imperial College London, London, UK
- MRC Centre for Environment and Health, Imperial College London, London, UK
| |
Collapse
|
5
|
Cichocka‐Jarosz E, Dölle‐Bierke S, Jedynak‐Wąsowicz U, Sabouraud‐Leclerc D, Köhli A, Lange L, Papadopoulos NG, Hourihane J, Nemat K, Scherer Hofmeier K, Hompes S, Ott H, Lopes de Oliveira L, Spindler T, Vogelberg C, Worm M. Cow's milk and hen's egg anaphylaxis: A comprehensive data analysis from the European Anaphylaxis Registry. Clin Transl Allergy 2023; 13:e12228. [PMID: 36973951 PMCID: PMC10040951 DOI: 10.1002/clt2.12228] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2022] [Revised: 12/29/2022] [Accepted: 02/07/2023] [Indexed: 03/29/2023] Open
Abstract
BACKGROUND Cow's milk (CM) and hen's egg (HE) are leading triggers of anaphylaxis in early childhood. The aim of this study was to identify clinical phenotypes and therapeutic measures for CM anaphylaxis (CMA) compared to HE anaphylaxis (HEA) in children up to 12 years of age, based on a large pan-European dataset from the European Anaphylaxis Registry. METHODS Data from 2007 to 2020 on clinical phenotypes and treatment from 10 European countries, as well as Brazil, were analysed. The two-step cluster analysis was used to identify the most frequent phenotypes. For each trigger, three clusters were extracted based on sex, age, and existence of symptoms in four vitally important systems. RESULTS Altogether 284 children with CMA and 200 children with HEA were identified. They were characterised as male (69% vs. 64%), infants (65% vs. 61%), with a most frequent grade III of Ring&Messmer classification (62% vs. 64%), in CMA versus HEA, respectively. Respiratory symptoms occurred more often in CMA (91% vs. 83%, p = 0.010), especially in infants (89% vs. 79%, p = 0.008). Cardiovascular symptoms were less frequent in CMA (30% vs. 44%, p = 0.002), in both infants (33% vs. 46%, p = 0.027), and older children (25% vs. 42%, p = 0.021). The clusters extracted in the CMA group were characterised as: (1) mild dermal infants with severe GI (40%), 2. severe dermal (35%), 3. respiratory (25%). While in HEA group: 1. infants with severe GI and/or reduction of alertness (40%), (2) conjunctival (16%), (3) mild GI without conjunctivitis (44%). The severity of the reaction was independent from the amount of ingested allergen protein, regardless of trigger. The first-line adrenaline application differed between the countries (0%-92%, as well as the reasons for not administering adrenaline, p < 0.001). CONCLUSIONS Despite the similarity of their age, sex, and severity grade, the clinical profiles differed between the CMA and HEA children. Adrenaline was underused, and its administration was country dependent. Further studies are needed to assess to what extent the differences in the clinical profiles are related to matrix and/or absorption effects, and/or the allergen itself.
Collapse
Affiliation(s)
- Ewa Cichocka‐Jarosz
- Department of PaediatricsPulmonology, Allergy and Dermatology ClinicJagiellonian University Medical CollegeKrakowPoland
| | - Sabine Dölle‐Bierke
- Department of DermatologyVenerology and AllergologyCharité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu BerlinBerlin Institute of HealthBerlinGermany
| | - Urszula Jedynak‐Wąsowicz
- Department of PaediatricsPulmonology, Allergy and Dermatology ClinicJagiellonian University Medical CollegeKrakowPoland
| | | | - Alice Köhli
- Division of AllergologyUniversity Children's Hospital ZurichZürichSwitzerland
| | - Lars Lange
- Department of PaediatricsSt. Marien‐HospitalBonnGermany
| | - Nikolaos G. Papadopoulos
- Allergy Department2nd Paediatric ClinicUniversity of AthensAthensGreece
- Division of Infection Immunity and Respiratory MedicineUniversity of ManchesterManchesterUK
| | - Jonathan Hourihane
- Department of PaediatricsUniversity of Medicine and Health SciencesRoyal College of Surgeons in IrelandDublinIreland
| | - Katja Nemat
- Children's CentreDresden – FriedrichstadtDresdenGermany
| | | | - Stephanie Hompes
- Department of PaediatricsAltona Children's HospitalHamburgGermany
| | - Hagen Ott
- Division of Paediatric Dermatology and AllergologyChildren's Hospital Auf der BultHannoverGermany
| | - Lucila Lopes de Oliveira
- Department of PaediatricsFederal University of São Paulo – Escola Paulista de Medicina (UNIFESP‐EPM)São PauloBrazil
| | | | - Christian Vogelberg
- Department of Paediatric Pulmonology and AllergyUniversity Hospital Carl Gustav CarusTechnical University of DresdenDresdenGermany
| | - Margitta Worm
- Department of DermatologyVenerology and AllergologyCharité – Universitätsmedizin BerlinCorporate Member of Freie Universität BerlinHumboldt‐Universität zu BerlinBerlin Institute of HealthBerlinGermany
| |
Collapse
|
6
|
Tanno LK, Demoly P. Food allergy in the World Health Organization's International Classification of Diseases (ICD)-11. Pediatr Allergy Immunol 2022; 33:e13882. [PMID: 36433855 PMCID: PMC9828038 DOI: 10.1111/pai.13882] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2022] [Revised: 10/25/2022] [Accepted: 10/28/2022] [Indexed: 11/17/2022]
Abstract
There are increasing global data regarding the prevalence of food allergy and food-induced anaphylaxis. However, knowledge in morbidity and mortality epidemiological data is still not optimal, and international comparable standards remain poorly accessed. This information could in turn support better clinical practice and possibly prevent future severe reactions and avoidable fatalities. The International Classification of Diseases (ICD) is the standard diagnostic tool used for epidemiology, health management, and clinical purposes supported by the World Health Organization (WHO). It is also used to determine health care payment and reimbursement of providers and health care services in hospitals. Thanks to the academic and technical efforts under the ALLERGY in ICD-11 initiative the pioneer "Allergy and hypersensitivity conditions" section has been built under the "Disorders of the Immune System" chapter of the ICD-11. The "Food hypersensitivity" (FH) subsection is classified under the "Complex allergic or hypersensitivity conditions" section and "Food-induced anaphylaxis" is under the "Anaphylaxis" section. In order to inform the development of strategies to reduce preventable FHs/food allergies, the burden of disease in different healthcare settings and patient populations and their common etiologies need to be understood. Besides, greater specificity regarding clinical conditions and services delivered will provide payers, policy makers, and providers with better information to make major refinements to countries payment and reimbursement systems, including the design and implementation of pay-for-performance program.The new classification addressed to FHs will enable the collection of more accurate epidemiological data to support quality management of patients with FHs/food allergies, and better facilitate health care planning and decision-making and public health measures to prevent and reduce their morbidity and mortality. The improved logic and standardized definitions through the ICD-11 (and other WHO classifications) will also facilitate international comparisons of quality care and the sharing of best practice globally.
Collapse
Affiliation(s)
- Luciana Kase Tanno
- Division of Allergy, Department of Pneumology, Allergology and Oncology, University Hospital of Montpellier, Montpellier, France.,Institut Desbrest d'Epidémiologie et de Santé Publique, UMR UA-11, University of Montpellier - INSERM, Montpellier, France.,WHO Collaborating Centre on Scientific Classification Support, Montpellier, France
| | - Pascal Demoly
- Division of Allergy, Department of Pneumology, Allergology and Oncology, University Hospital of Montpellier, Montpellier, France.,Institut Desbrest d'Epidémiologie et de Santé Publique, UMR UA-11, University of Montpellier - INSERM, Montpellier, France.,WHO Collaborating Centre on Scientific Classification Support, Montpellier, France
| |
Collapse
|
7
|
Tanno LK, Molinari N, Annesi-Maesano I, Demoly P, Bierrenbach AL. Anaphylaxis in Brazil between 2011 and 2019. Clin Exp Allergy 2022; 52:1071-1078. [PMID: 35856139 PMCID: PMC9541456 DOI: 10.1111/cea.14193] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 06/20/2022] [Accepted: 06/21/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND There is a lack of population-based studies of anaphylaxis from low- and middle-income countries. This hampers public health planning and investments and may influence availability of adrenaline auto-injectors. OBJECTIVE We conducted the first national population-based study of anaphylaxis hospitalization in Brazil. METHODS Descriptive study using routinely reported data to the Brazilian Hospital Information System for the years 2011-2019. Information available is coded based on the International Classification of Diseases (ICD)-10 and covers main cause of hospitalization (primary cause) and any conditions contributing to it (secondary cause). RESULTS Over 9 years, we identified 5716 admissions due to anaphylaxis for all causes. The average hospitalization rate related to anaphylaxis was 0.71/100,000 population per year, with a 2.4% (95% CI 1.9%, 2.9%) increase per annum over the study period. Admissions were more frequent among females (52.8%), except for cases due to insect sting. Most admissions occurred in adulthood, from 30 to 59 years (36.3%) but 13.8% in preschool children (0-4 years). There were more young children admitted for food-related anaphylaxis, and more adults admitted for drug/iatrogenic-related anaphylaxis. There were 334 cases (5.8% of admissions) of fatal anaphylaxis over the study period, with increased case fatality rate over time. CONCLUSIONS AND CLINICAL RELEVANCE This is the first study of anaphylaxis hospital admissions using nation-wide data from a low- or middle-income country. Hospital admissions and fatalities from anaphylaxis in Brazil appear to be increasing.
Collapse
Affiliation(s)
- Luciana Kase Tanno
- Hospital Sírio-Libanês Sao Paulo, Sa˜o Paulo, Brazil.,University Hospital of Montpellier, Montpellier, France.,Desbrest Institute of Epidemiology and Public Health, UMR UA-11, INSERM University of Montpellier - INSERM, Paris, France.,WHO Collaborating Centre on Scientific Classification Support, Montpellier, France
| | - Nicolas Molinari
- University Hospital of Montpellier, Montpellier, France.,Desbrest Institute of Epidemiology and Public Health, UMR UA-11, INSERM University of Montpellier - INSERM, Paris, France
| | - Isabella Annesi-Maesano
- Desbrest Institute of Epidemiology and Public Health, UMR UA-11, INSERM University of Montpellier - INSERM, Paris, France
| | - Pascal Demoly
- University Hospital of Montpellier, Montpellier, France.,Desbrest Institute of Epidemiology and Public Health, UMR UA-11, INSERM University of Montpellier - INSERM, Paris, France.,WHO Collaborating Centre on Scientific Classification Support, Montpellier, France
| | - Ana Luiza Bierrenbach
- Hospital Sírio-Libanês Sao Paulo, Sa˜o Paulo, Brazil.,Sanas Epidemiology and Research, Sa˜o Paulo, Brazil
| |
Collapse
|
8
|
Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia™) in peanut allergy: a profile of its use. DRUGS & THERAPY PERSPECTIVES 2021. [DOI: 10.1007/s40267-021-00868-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|